These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16854499)

  • 1. Impact of joined-up HIV harm reduction and multidrug resistant tuberculosis control programmes in Estonia: System dynamics simulation model.
    Atun RA; Lebcir RM; McKee M; Habicht J; Coker RJ
    Health Policy; 2007 May; 81(2-3):207-17. PubMed ID: 16854499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of an effective multidrug-resistant tuberculosis control programme in the setting of an immature HIV epidemic: system dynamics simulation model.
    Atun RA; Lebcir R; Drobniewski F; Coker RJ
    Int J STD AIDS; 2005 Aug; 16(8):560-70. PubMed ID: 16105192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High coverage with HAART is required to substantially reduce the number of deaths from tuberculosis: system dynamics simulation.
    Atun RA; Lebcir RM; Drobniewski F; McKee M; Coker RJ
    Int J STD AIDS; 2007 Apr; 18(4):267-73. PubMed ID: 17509178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Global situation of TB and its control].
    Shimao T
    Kekkaku; 1999 Feb; 74(2):83-90. PubMed ID: 10191600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies.
    Maher D; Harries A; Getahun H
    Trop Med Int Health; 2005 Aug; 10(8):734-42. PubMed ID: 16045459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV infection and multidrug-resistant tuberculosis: the perfect storm.
    Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K
    J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam.
    Hammett TM; Wu Z; Duc TT; Stephens D; Sullivan S; Liu W; Chen Y; Ngu D; Des Jarlais DC
    Addiction; 2008 Jan; 103(1):137-45. PubMed ID: 18028519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections.
    Viveiros M; Martins M; Couto I; Rodrigues L; Machado D; Portugal I; Amaral L
    Expert Rev Anti Infect Ther; 2010 Apr; 8(4):465-80. PubMed ID: 20377340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis deaths in countries with high HIV prevalence: what is their use as an indicator in tuberculosis programme monitoring and epidemiological surveillance?
    Maher D; Watt CJ; Williams BG; Raviglione M; Dye C
    Int J Tuberc Lung Dis; 2005 Feb; 9(2):123-7. PubMed ID: 15732729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing prevalence of HIV, and persistent high-risk behaviours among drug users in Bangladesh: need for a comprehensive harm reduction programme.
    Islam MM; Conigrave KM
    Drug Alcohol Rev; 2007 Jul; 26(4):445-54. PubMed ID: 17564883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Global Fund's leadership on harm reduction: 2002-2009.
    Atun R; Kazatchkine M
    Int J Drug Policy; 2010 Mar; 21(2):103-6. PubMed ID: 20171865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of harm reduction in Central and Eastern Europe and Central Asia.
    Sarang A; Stuikyte R; Bykov R
    Int J Drug Policy; 2007 Mar; 18(2):129-35. PubMed ID: 17689355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
    Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
    Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tuberculosis in Poland, Europe, and world. Part II--mortality, drug resistance and HIV infection].
    Zielonka TM
    Pol Merkur Lekarski; 2006 Sep; 21(123):253-61. PubMed ID: 17163187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coverage to curb the emerging HIV epidemic among injecting drug users in Pakistan: delivering prevention services where most needed.
    Emmanuel F; Fatima M
    Int J Drug Policy; 2008 Apr; 19 Suppl 1():S59-64. PubMed ID: 18281206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the growing HIV-1 epidemic on multidrug-resistant tuberculosis control in Latvia.
    Morozova I; Riekstina V; Sture G; Wells C; Leimane V
    Int J Tuberc Lung Dis; 2003 Sep; 7(9):903-6. PubMed ID: 12971677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug use and HIV/AIDS in China.
    Liu Z; Lian Z; Zhao C
    Drug Alcohol Rev; 2006 Mar; 25(2):173-5. PubMed ID: 16627308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV epidemic in Estonia in the third decade of the AIDS era.
    Rüütel K; Uusküla A
    Scand J Infect Dis; 2006; 38(3):181-6. PubMed ID: 16507499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.